Bristol Myers Squibb Named to Dow Jones Sustainability Index North America
PRINCETON, NJ / ACCESSWIRE / June 28, 2024 / Bristol Myers Squibb Company
Recognition underscores BMS' commitment to innovation, responsibility and growth
Bristol Myers Squibb (NYSE:BMY) has been named to the prestigious 2023 Dow Jones Sustainability Index (DJSI) North America, validating the company's meaningful progress, evolved strategy and aspirational goals toward its environmental, social and governance efforts.
BMS has made significant strides toward their ESG goals, including efforts to increase workforce representation, reduce environmental impact, enhance data privacy and cyber security programs and establish principles for responsible artificial intelligence.
Additionally, the company has strengthened corporate governance by incorporating new ESG metrics into executive compensation.
The DJSI North America represents the top 20% of the largest 600 North American companies in the S&P Global Broad Market Index who have demonstrated outstanding performance across economic, environmental and social criteria. The index is a widely respected benchmark for investors who integrate sustainability considerations into their portfolios.
"BMS is committed to driving long-term business value and continuously improving our ESG performance," said Korab Zuka, vice president, Purpose and ESG, Bristol Myers Squibb. "The recognition by the Dow Jones Sustainability Index North America honors the company's efforts to enhance our sustainability practices and positively impact the health of people, society and the planet."
BMS' ESG strategy focuses on advancing patient health and fostering a high-performing, inclusive workforce, while expanding the boundaries of science and reducing environmental impact.
Learn more about BMS' ESG strategy and commitments in its 2023 ESG Report.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X (formerly Twitter), YouTube, Facebook and Instagram.
Contact Info:
Spokesperson: Bristol Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com
SOURCE: Bristol Myers Squibb Company
View the original press release on accesswire.com
-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations